Stem cell clinical trials or paid treatment abroad: how to decide

A U.S. stem cell clinical trial charges the patient nothing and carries the strongest safety oversight, but eligibility is narrow, the wait is long, and a randomized trial gives you a 50% chance of placebo. Paid treatment abroad is a clinical service, not a trial: you pay out of pocket, you receive cells within weeks, and the oversight is lighter.

If you qualify and have time and accept randomization, apply to the trial.

The four questions, in order
U.S. trial path Free, waitlist Treatment abroad Paid, scheduled. Weeks, not years.

Is paid treatment abroad the same as a clinical trial?

More than 1,200 clinical trials of mesenchymal stromal cells had been registered on ClinicalTrials.gov by May 2021, some of them U.S.-based. Many have recruited for conditions a patient considering treatment in Mexico is also thinking about: MS, Crohn's, lupus, knee OA, certain cardiomyopathies. The cells used in those trials are often the same kind of cell used at a place like ours: the same source tissue, released against the same kinds of tests. So why isn't the answer always "do the trial"?

Because the trial is a different product. The cells may be the same; the experience is not. A trial is a research instrument first and a treatment second: its job is to generate generalizable knowledge, and almost every constraint follows from that. A paid treatment is the opposite: its job is to deliver care to one specific patient, and almost every constraint follows from that. Same intervention, different goals, different rules.

U.S. clinical trial

A research instrument.

Designed to test a hypothesis. Run by a sponsor (NIH, biotech, academic center). Patients are subjects; cells are the experimental intervention; outcomes feed regulatory submissions.

Funding
Sponsor
Patient cost
No charge
Outcome owner
FDA / sponsor
You may get
Placebo

Treatment abroad

A clinical service.

Designed to deliver an intervention to one patient. Run by a clinic. The patient is the paying party; cells are a product; outcomes are tracked for that patient's record.

Funding
Patient
Patient cost
Out of pocket
Outcome owner
Patient
You will get
Cells
Read moreShow less

One reading of this is that the trial is the higher-integrity choice: it contributes to knowledge, it's free, it's under FDA supervision. That reading is half right. The other half is: a trial is not a treatment plan. The trial's job ends when its data is submitted. If the cells worked for you specifically, the trial doesn't follow you into year three. If they didn't, the trial doesn't compensate you for the year you spent in placebo. The trial's accountability is to the question, not to you.

Should you apply to the trial or pay for treatment?

If you're trying to choose, these are the four questions in the order that narrows the field. Earlier questions decide the later ones: a "no" on Q1 closes the trial path and sends you to Q4. The verdict at the bottom is what we'd tell a friend, not a recommendation to the public.

  1. Is there an actively recruiting trial for your specific indication, and do you meet its inclusion criteria?

    Eligibility

    If yes

    Go to Q2. ClinicalTrials.gov (opens in a new tab) is the search; your local academic center is the next call.

    If no

    The trial path is closed. The question collapses to: paid treatment abroad, or no treatment. Skip to Q4.

  2. Can your condition tolerate 12–18 months from now to first infusion?

    Time

    If yes

    The trial is the higher-integrity choice. Go to Q3 to stress-test it.

    If no

    Progressive disease, age, or quality-of-life decline make the wait costly. The faster path becomes proportionally more defensible.

  3. Can you accept a 50% chance of receiving placebo or active comparator instead of the experimental cells?

    Randomization

    If yes

    This is the philosophical posture that makes trials work. The trial is the right choice. Apply.

    If no

    An honest "I want the cells, not a coin flip" is a legitimate stance. The trial path loses its case.

  4. If you've decided the trial isn't the path, can you absorb the out-of-pocket cost of the paid alternative without destabilizing your finances?

    Cost

    If yes

    Treatment abroad is a defensible choice. Vet the clinic carefully and proceed.

    If no

    Neither path is right today. Wait, save, or pursue conventional care. We'll tell you this in consult if it's what we see.

Trial path wins when

You qualify, you have time, you accept randomization. The trial is then unambiguously the higher-integrity, lower-cost, more-rigorously-monitored choice.

Treatment abroad wins when

You don't qualify, or you do but can't wait, or you can wait but won't accept placebo, and you can absorb the cost. Otherwise neither path is right today.

Will you qualify for a stem cell clinical trial?

Of patients who screen for a typical phase-2 MSC trial, roughly 3–8% meet all inclusion and exclusion criteria.

The most common pattern we see is a patient who reads about an active trial, gets excited, and assumes "active recruitment" means "available to them." It rarely does. Trials are designed to test the intervention in a clean population, which means almost every comorbidity, prior treatment, or unusual lab value is a reason to exclude you. The numbers below are a representative funnel for a mid-stage MSC trial in autoimmune disease. They are not Celva's numbers; they're industry typical.

  1. Heard about the trial Self-referral or clinician100 baseline
  2. Passed phone screen Age, diagnosis, geography60 −40 dropped
  3. Records review passed Disease severity in window32 −28 dropped
  4. On-site screening passed Labs, imaging, comorbidities14 −18 dropped
  5. Consented + enrolled Signed ICF; randomized6 ≈6% of original
  6. Received the actual cells 1:1 randomization3 50% got placebo

Of the original 100 patients who started the process, 3 will receive the experimental cells. If you've heard "I tried to get into a trial and it didn't work out", this funnel is why.

Read moreShow less

The dropoff happens at every stage and the dropoff has a structure. The phone-screen losses are usually geography and rough diagnosis. The records-review losses are disease severity (too mild or too severe, trials want the middle). The on-site losses are comorbidities (kidney disease, prior cancer, heart failure, recent surgery, all common, all disqualifying). The randomization halves whatever's left.

Back to the four questions

How long does a stem cell clinical trial take?

Time is the second variable patients underestimate. The trial timeline is dominated by waiting: for screening slots, for randomization, for the trial to open at a center near you. The treatment-abroad timeline is dominated by preparation: records review, financing, travel arrangements. Both are real work, but they live on completely different clocks.

U.S. clinical trial Median elapsed: ~14 months from first email to first infusion

  1. Find & contact
  2. Screening
  3. Wait for slot
  4. Enroll → infusion

Treatment abroad (Celva) Usually weeks from first call to treatment day. No fixed time is promised.

  1. 15-minute call
  2. Records
  3. Physician team review
  4. Written answer and quote
Same patient, two timelines, one scale.

Patients with progressive disease: MS that's actively flaring, RA that's failing biologics, autoimmune neuropathy losing function quarter over quarter, are the population for whom this delta is decisive. A year in the trial waiting room is a year of disease progression. A wait measured in weeks is a different cost-benefit calculation. This is not an argument that the trial is wrong; it is an argument that the trial is slow. If you have time, the trial's slowness is fine. If you don't, it isn't.

Back to the four questions

Clinical trial vs. paid treatment abroad, line by line

Each row is a difference that bites at some point in the patient experience. Some favor the trial. Some favor treatment abroad. No single column wins; the question is which row matters most for your situation.

U.S. clinical trial Treatment abroad (Celva model)
Cost to patient No charge to the patient Trial pays for the intervention, screening, sometimes travel. You may pay incidental costs (parking, time off work). Paid out of pocket You pay the clinic directly. Insurance does not reimburse. HSA and FSA eligibility depends on your plan.
Eligibility Narrow Strict inclusion/exclusion: age, disease severity, prior treatments, comorbidities. ~3–8% of screeners qualify. Broader, but not unlimited A significant share of inquiries are declined or deferred, for safety or expectation reasons. See how we vet candidates.
Randomization Usually yes Most phase-2/3 trials randomize 1:1, 50% chance of placebo or active comparator, not the experimental cells. Never You receive cells. No randomization, no blinding, no placebo arm.
Read moreShow less
U.S. clinical trialTreatment abroad (Celva model)
Time to infusion ~12–18 months Identify trial → screening (3–6 mo) → enrollment → randomization → first infusion. Plus the wait for the trial to be open. Weeks, with no fixed time promised A 15-minute call with a patient coordinator → records → physician team review → a written answer and an itemized quote → scheduling → treatment day. See the patient experience.
Safety oversight IRB, DSMB, FDA Three layers. Adverse events reportable. Trial can be halted by any of them. Strongest patient-safety apparatus in medicine. COFEPRIS + a full hospital Care is regulated by COFEPRIS and given inside Hospital Angeles, Tijuana. See what happens if something goes wrong. Strong but not equivalent to trial oversight.
Cell product One specific product The trial's product, often allogeneic UC-MSC or BM-MSC, manufactured at a specific cGMP facility. Dose fixed by protocol. Our product Donor (allogeneic) cells of three types: umbilical-cord MSCs most often, bone-marrow MSCs, and chondrocytes. Made by a process developed in-house. Dosed by weight. See counts, viability, and dose.
Follow-up Extensive, time-limited Per protocol: often 12 or 24 months of structured visits, with labs and PROs at every protocol-specified visit and imaging on the cadence your case calls for. Then the trial ends and follow-up stops. Lighter, indefinite Follow-up calls at 1 week, then at 1, 3 and 6 months, then once a year, by phone or video, from your patient coordinator or aftercare specialist. A physician joins when needed. No scheduled labs or imaging. No formal endpoint. Your local doctor remains primary.
Geography Often distant U.S. trials concentrate at academic centers: Boston, Houston, Cleveland, Stanford. May require relocation or repeat travel. Single day One day trip to Tijuana. Most patients are driven back to San Diego the same day.
What's "approved" downstream Whatever you got If the trial drug is later approved, you may have priority access. If the trial fails, the drug is gone. Not regulated for U.S. approval This is a commercial service, not a path toward FDA approval. The intervention exists only in the country it was delivered.
Re-treatment Not on protocol You receive the protocol-specified doses. Re-treatment outside the trial is not the trial's concern. Possible, paid Whether a second treatment makes sense is decided at your follow-up reviews. A second treatment is paid. Not all clinics offer this honestly.
Contribution to science Direct Your data (anonymized) feeds the trial; the trial feeds the field. This is the real ethical pull of the trial path. Minimal Outcomes data exists in your chart but does not aggregate into peer-reviewed evidence. We say this plainly.
What the result feels like Bigger meaning, smaller chance If it works, you helped prove it works. If it doesn't, you were part of finding that out. Either way, an answer. Personal stake, no big "result" You either benefited or you didn't. The cells worked for you or they didn't. No external finding to point at.

What we won't say about clinical trials

Some clinics frame this comparison as a slam-dunk for the paid path. We don't, because the framing is dishonest. The trial path has real advantages we can't match. Three statements we won't make, in any consult or any page on this site:

  • "Trials are slow because of bureaucracy."

    Trials are slow because they're structured to generate generalizable, regulator-grade evidence. The slowness is the feature, not the bug. We're faster because we're doing a different, less rigorous thing.

  • "You'd be better off paying than waiting for a placebo."

    Maybe. But only sometimes, and only for some patients. The phrase that you might hear at a sales-driven clinic, "why gamble on placebo?", pretends that paid treatment has the same evidence base as the trial it's competing against. It doesn't.

  • "Mexico has the same standards."

    Mexico has different standards. Some are stronger than what U.S. wellness clinics meet. None are equivalent to an FDA-supervised RCT. Anyone telling you otherwise is selling.

If you're a candidate for a trial, the trial is usually the right first call.

We tell candidates this in consult, and decline patients who'd be better served by a trial that's actively recruiting for their indication.

Book a call Search ClinicalTrials.gov (opens in a new tab)